Jun 13, 2024 8:00am EDT Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
May 28, 2024 8:00am EDT Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
May 13, 2024 4:45pm EDT Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
Mar 26, 2024 8:30am EDT Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 01, 2024 7:49am EST Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
Feb 28, 2024 8:30am EST Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Nov 14, 2023 6:00am EST Vivani Medical Provides Business Update and Reports Third Quarter Financial Results